[Colloid drug delivery systems: a response to therapeutic expectations arising from biotechnological advances?].
New and fascinating advances in biotechnology have open new perspectives since the use of monoclonal antibodies for therapeutic application, particularly cancer, has been approved. Over the last two decades, numerous research teams have demonstrated that the progression of cancer is often associated with an over-expression of one or several proteins, called tumor antigens. In order to target tumors specifically, researchers have tried to couple monoclonal antibodies with colloid vectors such as liposomes, nanoparticles, and emulsions containing cytotoxic compounds. Use of these conjugated vector-antibody systems for the treatment of cancer is designed to target cancerous cells while sparing healthy cells. We present here a discussion on the synergy between biotechnology and modern molecular pharmotechnology, opening new horizons for therapy.
Goldstein
D
D
Département de pharmacie galénique, Ecole de pharmacie, Université hébraïque de Jérusalem, Ein Kherem Campus, PO BOX 12065, 91120 Jérusalem, Israel.
Lambert
G
G
Puisieux
Fr
F
Benita
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000627:therapeutic use*; D001709:Biotechnology; D003102:Colloids; D016503:Drug Delivery Systems; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003102:Colloids; D018796:Immunoconjugates